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CREBH-FGF21 axis improves 
hepatic steatosis by suppressing 
adipose tissue lipolysis
Jong-Gil Park1, Xu Xu1, Sungyun Cho2, Kyu Yeon Hur3, Myung-Shik Lee4, Sander Kersten5 & 
Ann-Hwee Lee1,2
Adipose tissue lipolysis produces glycerol and nonesterified fatty acids (NEFA) that serve as energy 
sources during nutrient scarcity. Adipose tissue lipolysis is tightly regulated and excessive lipolysis 
causes hepatic steatosis, as NEFA released from adipose tissue constitutes a major source of TG 
in the liver of patients with nonalcoholic fatty liver diseases. Here we show that the liver-enriched 
transcription factor CREBH is activated by TG accumulation and induces FGF21, which suppresses 
adipose tissue lipolysis, ameliorating hepatic steatosis. CREBH-deficient mice developed severe hepatic 
steatosis due to increased adipose tissue lipolysis, when fasted or fed a high-fat low-carbohydrate 
ketogenic diet. FGF21 production was impaired in CREBH-deficient mice, and adenoviral overexpression 
of FGF21 suppressed adipose tissue lipolysis and improved hepatic steatosis in these mice. Thus, our 
results uncover a negative feedback loop in which CREBH regulates NEFA flux from adipose tissue to the 
liver via FGF21.
Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of liver disorders from simple steatosis, which 
is characterized by excess accumulation of triglyceride (TG) within hepatocytes, to nonalcoholic steatohepatitis 
(NASH) that accompanies hepatocyte death, liver inflammation and fibrosis1,2. NAFLD is closely associated with 
obesity and insulin resistance, and is considered as the hepatic manifestation of the metabolic syndrome. NAFLD 
is the most common liver disease in industrialized countries, and recognized as a global public health problem 
due to its rising prevalence in parallel with the epidemic obesity3.
Hepatic steatosis is caused by an imbalance in TG homeostasis in the liver. Increased flow of fatty acids to 
hepatocytes from adipose tissues or from the diet, increased de novo lipogenesis, decreased oxidative disposal 
of fatty acids, or impaired export of TG as very low density lipoprotein (VLDL) is expected to result in a net 
increase in hepatic TG content4. The relative contributions by these factors to human NAFLD have yet to be 
clearly defined. Interestingly, a study has demonstrated that nonesterified fatty acids (NEFA) that originate from 
adipose tissues account for the majority of hepatic TG in NAFLD patients5, implicating that dysregulation of 
adipose tissue lipolysis may critically contribute to fatty liver diseases. Consistent with this notion, it has been 
shown that disruption of lipolytic enzymes or the regulatory proteins of lipolysis strongly impacts TG deposition 
in the liver6–9. Adipose tissue lipolysis is tightly regulated by neuroendocrine signals, among which catechola-
mines and insulin are known to play central roles. β -adrenergic stimulation activates adipose triglyceride lipase 
(ATGL) and hormone-sensitive lipase (HSL) via the cAMP/protein kinase A (PKA) signaling pathway, leading 
to enhanced lipolysis in white adipocytes10. PKA directly phosphorylates HSL and perilipin-1, a lipid droplet 
(LD)-associated protein, increasing HSL activity and its translocation onto LD surface11–14. PKA-phosphorylation 
of perilipin-1 also stimulates ATGL, as CGI-58, an important activator of ATGL is released from the phospho-
rylated perilipin-115,16. In contrast, insulin potently inhibits both basal and catecholamine-stimulated lipolysis by 
activating phosphodiesterase-3B that decreases cAMP level, and consequently represses HSL in the fed state10.
Cyclic AMP-responsive element-binding protein H (CREBH, encoded by Creb3l3) is a bZiP transcription 
factor that is highly expressed in the liver17,18. CREBH is synthesized as an ER precursor form and proteolytically 
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activated by Golgi-localized proteases. These site 1 and site 2 proteases liberate the N-terminal portion of CREBH, 
allowing it to act as a transcriptional activator19. CREBH is emerging as a critical regulator of glucose and lipid 
metabolism20. It has been shown that CREBH is transcriptionally activated by PPARα and the glucocorticoid 
receptor21,22, and promotes gluconeogenesis22, plasma TG clearance17, and lipid droplet formation in the liver23. 
It has been also reported that CREBH deficient mice are susceptible to hepatic steatosis when fasted17, or fed an 
atherogenic Paigen diet24. However, the underlying mechanism and the precise role of CREBH in hepatic TG 
homeostasis remained unknown or controversial. Zhang and colleagues demonstrated that a group of genes 
involved in de novo lipogenesis, fatty acid elongation, fatty acid oxidation were down-regulated in the liver of 
CREBH deficient mice fed the Paigen diet compared to WT controls24. However, it was unexplored whether this 
gene expression change impacts TG accumulation in CREBH deficient liver, or reflects the consequence of severe 
steatosis in these mice.
In this study, we determined the source of TG accumulated in the liver of CREBH deficient mice, and explored 
the mechanism by which CREBH controls TG homeostasis in the liver. We demonstrate that CREBH-deficient 
mice develop severe hepatic steatosis, when fasted or fed a high-fat low-carbohydrate ketogenic diet (KD), condi-
tions in which fatty acids serve as major energy source. We find that adipose tissue lipolysis is marked increased 
in CREBH-deficient mice, suggesting that the increased flow of NEFA from adipose tissue to the liver is primarily 
responsible for the liver steatosis in CREBH deficient mice. In contrast, de novo lipogenesis, fatty acid oxidation, 
and VLDL secretion are largely unaffected in CREBH deficient liver. We also demonstrate that fibroblast growth 
factor (FGF) 21 is a critical CREBH target that ameliorates hepatic steatosis. FGF21 is a member of FGF family 
mainly secreted by the liver25,26 and acts as a metabolic regulator exerting various metabolic benefits, including 
weight loss and improvement of glucose homeostasis27–32. We find that hepatic FGF21 expression correlates well 
with the degree of steatosis in various rodent models, and CREBH plays a critical role in FGF21 expression. 
Severe hepatic steatosis and inflammation in KD-fed CREBH deficient mice were substantially reversed by ade-
noviral overexpression of FGF21. Coupled with our previous finding that CREBH is activated in fatty livers23, we 
propose that CREBH plays a central role in hepatic TG homeostasis by inducing FGF21, which suppresses NEFA 
flux to the liver, thereby ameliorating hepatic steatosis.
Results
CREBH deficiency increases hepatic TG due to increased adipose tissue lipolysis. CREBH defi-
cient (Creb3l3−/−) mice fed normal chow diet exhibited increased plasma and hepatic TG levels compared with 
WT mice, when measured after a 16 h fast (Fig. 1A,B). Oil red O staining of frozen liver sections also showed 
higher amount of neutral lipids in Creb3l3−/− hepatocytes than in WT controls (Fig. 1C). In contrast, plasma and 
hepatic TG levels in the fed state were not significantly different between WT and Creb3l3−/− mice (Fig. 1A–C).
To determine the cause of severe fasting-induced hepatic steatosis in Creb3l3−/− mice, we first asked whether 
adipose tissue lipolysis was increased in these mice. Prolonged fasting increased plasma glycerol and NEFA 
levels in both WT and Creb3l3−/− mice, indicating enhanced adipose tissue lipolysis during nutrient scarcity. 
Interestingly, Creb3l3−/− mice exhibited significantly higher fasting plasma glycerol and NEFA levels than the 
WT mice (Fig. 1D,E), suggesting that the loss of CREBH further increased adipose tissue lipolysis. Consistent 
with this, HSL phosphorylation at protein kinase A (PKA) sites (Ser-563 and Ser-660) in WAT was significantly 
increased in Creb3l3−/− compared to the WT mice in the fasted state33 (Fig. 1F,G, Supplementary Fig. 1A). 
Perilipin phosphorylation as revealed by the band shift in western blot34 was also increased in Creb3l3−/− com-
pared to WT mice (Fig. 1F, Supplementary Fig. 1A). ATGL abundance tended to be higher in Creb3l3−/− WAT 
than in WT controls (Fig. 1F, Supplementary Fig. 1A), but this difference did not reach statistical significance. 
Insulin is a critical regulator of adipose tissue lipolysis, suppressing lipase activity through the Akt kinase-PKA 
pathway35. Fasting decreased plasma insulin and glucose levels in both WT and Creb3l3−/− mice to similar 
degrees (Fig. 1H,I). Creb3l3−/− mice exhibited a modestly improved glucose tolerance (Fig. 1J), excluding the 
possibility that the increased lipolysis in Creb3l3−/− mice might be due to low insulin level or compromised insu-
lin action. These data suggest that CREBH regulates adipose tissue lipolysis in an insulin-independent manner.
We next investigated whether de novo lipogenesis, VLDL secretion rate, fatty acids oxidation, and ketogenesis 
were altered in Creb3l3−/− mice, contributing to the increased hepatic steatosis. We found comparable expression 
of major lipogenic transcription factors, Srebf1, Srebf2, and ChREBP, and their target genes, such as Fasn, Acacb, 
and Scd1 between WT and Creb3l3−/− mice in the fed state (Fig. 2A). Srebf1 and its target genes were markedly 
downregulated by fasting in both WT and Creb3l3−/− mice, likely reflecting normal insulin-mediated regulation 
of these genes. In contrast, fasting-induced expression of Apoa4, a representative CREBH target gene was mark-
edly downregulated in Creb3l3−/− liver (Supplementary Fig. 1B), consistent with previous report23. Furthermore, 
overexpression of the constitutively active CREBH(N) had no effect on TG synthesis in primary mouse hepato-
cytes using glycerol and oleic acid as substrates (Supplementary Fig. 1C), suggesting that CREBH has minimal 
role in lipogenesis. The scavenger receptor CD36 involved in fatty acid uptake was similarly expressed between 
WT and Creb3l3−/− livers (Supplementary Fig. 1B). The abundance of PPARα , the central transcriptional reg-
ulator of fatty acid oxidation and ketogenesis, was comparable between WT and Creb3l3−/− livers (Fig. 2B). 
Consistently, mRNA levels of PPARα target genes, such as Acox1, Cpt2, Hmgcs2, Hadh, Acadm, and Acadl 
were similar between WT and Creb3l3−/− livers, except Cpt1a which appeared to be regulated by both CREBH 
and PPARα (Fig. 2C). Western blotting also confirmed normal expression of Hmgcs2 protein, the rate-limiting 
enzyme for ketogenesis, in Creb3l3−/− liver (Supplementary Fig. 1D). Importantly, fatty acid oxidation capacity 
was comparable between WT and Creb3l3−/− liver lysates (Fig. 2D). Creb3l3−/− mice exhibited slightly higher 
fasting plasma ketone levels compared with the WT mice, likely reflecting the increased flow of fatty acids to 
the liver to serve as ketogenic substrates (Fig. 2E). Consistent with this scenario, in vitro ketone production rate 
was comparable between WT and Creb3l3−/− primary hepatocytes, when octanoic acids were provided as sub-
strate (Supplementary Fig. 1E). Similarly, overexpression of CREBH(N) had no effect on ketone production in 
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primary hepatocytes (Supplementary Fig. 1F). Finally, there was no noticeable difference in the hepatic VLDL-TG 
production rate between WT and Creb3l3−/− mice (Fig. 2F). Taken together, these data suggest that the severe 
fasting-induced hepatic steatosis in Creb3l3−/− mice is primarily due to increased adipose tissue lipolysis, whereas 
de novo lipogenesis, VLDL production, and fatty acid oxidation were unaffected in Creb3l3−/− mice.
Severe hepatic steatosis of CREBH deficient mice on ketogenic diet. High-fat, low-carbohydrate 
ketogenic diet (KD) has metabolic effects similar to fasting, shifting the energy source from carbohydrates to 
fatty acids, which are oxidized in the liver to produce ketone bodies36. We tested whether, similarly to fasting, 
Figure 1. CREBH deficiency exacerbates fasting-induced hepatic steatosis by increasing adipose tissue 
lipolysis. (A) Plasma TG levels measured at fed state or after a 16 h fast (n = 5 per group). (B) Hepatic TG levels 
(n = 6–9 per group). (C) Oil red O staining of liver sections. Scale bar, 200 μ m. (D) Plasma glycerol, and (E) 
NEFA levels (n = 6 per group). (F) HSL and perilipin phosphorylation, and ATGL expression in WAT measured 
by western blotting. (G) Quantification of Ser-563 phospho-HSL levels normalized to total HSL. (H) Plasma 
insulin and (I) blood glucose levels (n = 6 per group). (J) Intraperitoneal glucose tolerance test (GTT) (n = 6 per 
group). Data are shown as mean ± s.e.m. *P < 0.05, **P < 0.01.
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Figure 2. De novo lipogenesis, VLDL secretion, lipid oxidation, and ketogenesis in Creb3l3−/− mice.  
(A) Hepatic mRNA levels for each gene were determined by qRT-PCR (n = 4 per group). (B) Liver nuclear 
extracts were subjected to western blotting using antibodies against PPARα , CREBH and Lamin B1.  
(C) Hepatic mRNA levels of lipid oxidation-related genes determined by qRT-PCR (n = 4 per group). (D) Fatty 
acid oxidation activity in liver lysates (n = 3 per group). (E) Total plasma ketone bodies during fasting (n = 6 per 
group). (F) VLDL secretion assay (n = 6 per group). Data are shown as mean ± s.e.m. *P < 0.05.
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the KD caused severe steatosis in Creb3l3−/− mice. KD caused mild steatosis in WT mice, as determined by 
oil red O staining of the liver sections and biochemical quantification of hepatic TG and cholesterol contents 
(Fig. 3A–C). In stark contrast, Creb3l3−/− mice exhibited a dramatic increase in hepatic TG level compared with 
the WT mice (Fig. 3B). Hepatic cholesterol levels were modestly increased in Creb3l3−/− mice (Fig. 3C). H&E 
staining confirmed the presence of ballooned hepatocytes with pale cytoplasm in Creb3l3−/− mice, a distinc-
tive feature of hepatic steatosis (Supplementary Fig. 2A). KD also induced hepatomegaly in Creb3l3−/− mice, 
resulting in a more than 60% increase in liver to body weight ratio (Fig. 3D,E). Creb3l3−/− mice lost more body 
weight than the WT on KD (Supplementary Fig. 2B). Body weight loss correlated well with the reduced fat mass 
(Supplementary Fig. 2C). KD dramatically increased plasma glycerol and NEFA levels in Creb3l3−/−, but not in 
WT mice (Fig. 3F,G). Creb3l3−/− mice also exhibited increased HSL and perilipin phosphorylation, and increased 
ATGL abundance in WAT compared with the WT controls (Fig. 3H), indicating that CREBH deficiency led to 
dysregulated adipose tissue lipolysis. Plasma TG and ketone body levels measured in the fed state were also mark-
edly higher in Creb3l3−/− than in WT mice on KD (Fig. 3I,J). Interestingly, the expression of PPARα and its target 
genes was impaired in Creb3l3−/− mice on KD (Supplementary Fig. 2D,E), which might have contributed to the 
severe steatosis phenotype of these mice. The underlying mechanism for the reduced expression of PPARα in 
CREBH deficient liver remains to be determined. Lipogenic transcription factors and enzymes were unchanged 
in Creb3l3−/− mice as compared with WT mice (Supplementary Fig. 2F).
Hepatic steatosis often progresses to NASH with associated liver damage, fibrosis, and inflammation. We 
next investigated whether the severe hepatic steatosis in Creb3l3−/− mice on KD progresses to NASH. KD 
caused a marked increase in plasma ALT levels in Creb3l3−/− mice, indicating the presence of liver damage 
(Fig. 4A). Trichrome staining of the liver sections revealed a pronounced deposition of collagen in the liver of 
Creb3l3−/− mice (Fig. 4B). Infiltration of inflammatory cells was also observed in the liver of Creb3l3−/− mice 
fed KD (Fig. 4C). Consistent with these histological observations, liver fibrosis-related genes such as Col1a1, 
TGF-beta1 and Acta2, and inflammatory genes such as MCP-1, KC, MIP-1α , CD11c and F4/80, were highly 
induced Creb3l3−/− mice (Fig. 4D,E). These data suggest that CREBH deficient mice are highly susceptible to 
NASH on KD.
CREBH-induced FGF21 suppresses lipolysis in adipose tissue. We next asked how liver-expressed 
CREBH regulates adipose tissue lipolysis. We reasoned that CREBH might induce a secretory protein(s) that 
acts on adipocytes to suppress lipolysis. An obvious candidate for this was FGF21, which has been identified as 
a direct CREBH-target and possesses an anti-lipolytic function31,32,37. In addition, we found that hepatic FGF21 
expression was highly increased in various animal models of steatosis, consistent with previous reports38–40. 
Remarkably, there was a strong correlation between hepatic FGF21 mRNA and hepatic TG levels, suggesting that 
hepatic TG content determines FGF21 transcription (Fig. 5A). Given that CREBH is activated in fatty livers23, 
we hypothesized that fatty livers produce FGF21 via CREBH to suppress lipolysis of adipose tissue, constituting 
a negative regulatory feedback loop. To test the hypothesis, we first measured hepatic FGF21 mRNA and plasma 
FGF21 protein levels in WT and Creb3l3−/− mice. Consistent with previous reports17,18, hepatic FGF21 expression 
was strongly induced by fasting in WT, but not in Creb3l3−/− mice (Fig. 5B). Plasma FGF21 protein level was 
also marked lower in Creb3l3−/− than in WT mice (Fig. 5C). KD-induced FGF21 expression was also markedly 
diminished in Creb3l3−/− mice, indicating a major role of CREBH in hepatic FGF21 expression (Fig. 5D,E). 
Deletion of both CREBH and PPARα in mice almost completely abolished FGF21 expression induced by fasting 
(Supplementary Fig. 3A,B), and KD feeding (Supplementary Fig. 3C,D), suggesting that these two transcription 
factors cooperatively regulate FGF21 transcription in the liver.
We next tested whether FGF21 suppressed lipolysis in an ex vivo lipolysis assay. We produced FGF21 in 
primary mouse hepatocytes by infecting cells with recombinant adenoviruses expressing human FGF21 or 
CREBH(N), which would induce endogenous FGF21 (Fig. 5F). The conditioned media containing FGF21 were 
tested for the effects on the rate of glycerol release from adipose tissue slices freshly isolated from overnight 
fasted mice. Conditioned media from CREBH(N) adenovirus-infected cells containing a moderate level of FGF21 
modestly suppressed the glycerol release (Fig. 5G). A high dose of FGF21 in the conditioned media from FGF21 
adenovirus-infected cells further suppressed glycerol release, suggesting that FGF21 suppresses adipose tissue 
lipolysis (Fig. 5G). Glycerol release from isoproterenol-stimulated cells was also reduced by FGF21-containing 
culture supernatant, suggesting that FGF21 suppressed β -adrenergic stimulated lipolysis (Fig. 5G).
We next tested whether FGF21 overexpression ameliorates hepatic steatosis of Creb3l3−/− mice. We injected 
recombinant adenovirus expressing human FGF21 (Ad.hFGF21) into Creb3l3−/− mice (Fig. 6A), which were then 
placed on KD 2 days after the viral transduction. FGF21 overexpression markedly decreased plasma glycerol and 
NEFA levels in Creb3l3−/− mice fed KD (Fig. 6B,C), indicating that FGF21 inhibited lipolysis. HSL and perili-
pin phosphorylation was also reduced by FGF21 adenovirus in the WAT of Creb3l3−/− mice (Fig. 6D). Hepatic 
steatosis was improved by FGF21 overexpression in Creb3l3−/− mice, as determined by decreased hepatic TG 
content and liver size (Fig. 6E,F and Supplementary Fig. 4A). FGF21 also improved the hypertriglyceridemia of 
Creb3l3−/− mice on KD (Fig. 6G). Interestingly, FGF21 overexpression partially restored the expression of PPARα 
and its target genes, Acox1, Hmgcs2 and Cpt1a in Creb3l3−/− mice (Supplementary Fig. 4B,C), which might 
have helped to improve the hepatic steatosis. Finally, we analyzed whether FGF21 overexpression ameliorated 
hepatic fibrosis and inflammation of Creb3l3−/− mice fed KD. Plasma ALT levels were significantly reduced in 
Ad.hFGF21-injected mice compared with Ad.GFP group (Fig. 6H). Additionally, expression of the inflammatory 
markers such as Col1al, Acta2, MCP-1, MIP-1α and CD11c, were also reduced by FGF21 overexpression (Fig. 6I). 
These data suggest that FGF21 is a critical CREBH target that protects against heaptic steatosis and steatohepatitis.
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Discussion
In this study, we demonstrate that CREBH is activated by TG accumulation in the liver and induces FGF21, 
which suppresses lipolysis in adipose tissue, thereby limiting NEFA flow to the liver (Fig. 7). Impairment of the 
CREBH-FGF21 axis causes severe steatosis owing to the uncontrolled NEFA flow to the liver in fasted or KD-fed 
Figure 3. Loss of CREBH exacerbates hepatic steatosis upon ketogenic diet feeding. (A) Oil red O staining 
of liver sections. Mice were sacrificed in the ad libitum fed state. Scale bar = 200 μ m. (B) Hepatic TG (n = 10 
per group), and (C) cholesterol levels (n = 3 per group) in mice fed normal chow (ND) or ketogenic diet (KD) 
for 4 days. (D) Liver morphology. (E) The ratio of liver weight (LW) to body weight (BW). (n = 10 per group). 
(F) Plasma glycerol and (G) NEFA levels (n = 8 per group). (H) Western blotting analysis HSL and perilipin 
phosphorylation, and ATGL expression in WAT. (I) Plasma TG, and (J) total ketone bodies levels (n = 8 per 
group). Data are shown as mean ± s.e.m. *P < 0.05, **P < 0.01.
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mice. We propose that CREBH acts as a TG rheostat in the liver regulating the flow of fatty acids to the liver. We 
also show that CREBH deficient mice are susceptible to NASH, identifying CREBH as a potential target for NASH 
prevention and treatment.
It has been previously reported that CREBH deficient mice are susceptible to hepatic steatosis, but the under-
lying mechanism remained unclear17,24. Zhang and colleagues demonstrated that Creb3l3−/− mice fed athero-
genic Paigen diet high in saturated fat, cholesterol, and cholate developed severe hepatic steatosis, associated with 
decreased expression of genes involved in de novo lipogenesis, cholesterol synthesis, fatty acid oxidation, and 
lipoprotein metabolism24. However, it was unclear whether the alteration of hepatic gene expression profile by the 
loss of CREBH had a causal role in steatosis, or merely represented a consequence of severe steatosis. For exam-
ple, it is unlikely that decreased expression of lipogenic transcription factors and enzymes contributed to severe 
Figure 4. Hepatic inflammation and liver damage in CREBH deficient mice fed ketogenic diet. (A) Plasma 
alanine aminotransferase (ALT) levels un mice fed KD for 0, 4 and 7 days (n = 8 per group). (B) Mice were 
fed ND or KD for 4 days. Liver sections were stained with Masson’s trichrome. Scale bar = 200 μ m. (C) CD45 
immunostaining of liver sections. Scale bar = 400 μ m. (D) Hepatic mRNA levels of genes related to fibrosis 
and (E) inflammation determined by qRT-PCR (n = 4 per group). Data are shown as mean ± s.e.m. *P < 0.05, 
**P < 0.01.
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steatosis in Creb3l3−/− mice. In the current study, we systematically explored the mechanisms by which CREBH 
regulates hepatic TG content, and demonstrated that the increased NEFA delivery from adipose tissue to the liver 
is primarily responsible for the worsened hepatic steatosis in Creb3l3−/− mice. Intriguingly, Zhang et al.24 showed 
that fasting plasma ketone levels were lower in Creb3l3−/− than in WT mice, arguing that fatty acid oxidation was 
impaired in Creb3l3−/− mice. This is in stark contrast to our findings: increased plasma ketone levels in fasted or 
KD-fed Creb3l3−/− mice compared with WT controls, and comparable fatty acid oxidation activity in liver lysates 
between the two groups. Currently, we have no explanation for this discrepancy, as both studies used the same 
strain of Creb3l3−/− mice41. Notably, a recent independent study showed that Creb3l3−/− mice had higher ketone 
levels during starvation compared with the WT controls42, consistent with our observations. We speculate that 
the increased flow of fatty acids from WAT to the liver provides more substrate for ketogenesis, increasing plasma 
ketone levels in Creb3l3−/− mice.
FGF21 confers multiple metabolic benefits, which include improving hyperglycemia, hyperlipidemia, hepatic 
steatosis, and obesity43. Growing evidence suggests that WAT is a critical target organ responsible for these diverse 
metabolic effects of FGF2144–46. In the current study, we demonstrated that loss of CREBH decreased FGF21 
production from the liver, increased adipose tissue lipolysis and worsened hepatic steatosis, which was partially 
reversed by adenoviral overexpression of FGF21. We also showed that in vitro FGF21 suppressed lipolysis in 
mouse adipose tissue explants freshly prepared from overnight fasted mice, suggesting that CREBH-induced 
FGF21 suppressed adipose tissue lipolysis to ameliorate hepatic steatosis. It should be noted, however, that the 
effects of FGF21 on adipose tissue lipolysis is rather complex. An early study showed that FGF21 increased basal, 
but not isoproterenol-stimulated lipolysis in murine 3T3-L1 adipocytes47, whereas a subsequent study found no 
effect of FGF21 on basal lipolysis under similar experimental conditions37. In contrast, recent studies showed that 
FGF21 suppressed hormone-stimulated lipolysis in both 3T3-L1 and human adipocytes37,48. FGF21 knockout 
mice exhibited elevated plasma NEFA levels in fated state31, suggesting increased adipose tissue lipolysis in the 
absence of FGF21, which is consistent with our findings in Creb3l3−/− mice. In contrast, FGF21 injection lowered 
plasma NEFA in mice, supporting the role of FGF21 in the inhibition of adipose tissue lipolysis48,49. Interestingly, 
a recent paper proposed that FGF21 stimulates the flow of fatty acids into adipose tissues, resulting in the reduc-
tion of plasma NEFA levels49.
Figure 5. CREBH-induced FGF21 suppresses adipose tissue lipolysis. (A) Correlation between hepatic 
TG and FGF21 mRNA levels on Log2 scale in mice. Each symbol represents an individual mouse as indicated. 
R2 = 0.1995, P (two-tailed) = 0.0056. (B) Hepatic FGF21 mRNA levels determined by qRT-PCR (n = 4 per 
group). (C) Plasma FGF21 levels measured after a 16 h fast (n = 5 per group). (D) Hepatic FGF21 mRNA 
levels (n = 4 per group). (E) Plasma FGF21 protein levels (n = 7 per group). (F) Total FGF21 concentration in 
the conditioned media of the primary hepatocytes infected by Ad.GFP, Ad.CREBH(N) or Ad.hFGF21. Scale 
bar = 200 μ m. (G) Ex vivo lipolysis assay. Relative amount of glycerol released from WAT slice cultured in the 
presence of conditioned media for 3 hours. Isoproterenol (100 nM) was added to culture media to measure 
stimulated lipolysis. The results are the average of 5–6 independent experiments. A paired t-test was performed 
for statistical analysis. Data are shown as mean ± s.e.m. *P < 0.05, **P < 0.01.
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FGF21 exerts its biological activity through interaction with a cell surface receptor complex consisting of 
FGF1R1c and β -Klotho45,50–53. FGF receptor activation triggers various intracellular signaling pathways, but the 
specific pathways activated by FGF21 remains poorly understood54,55. Creb3l3−/− mice exhibited higher HSL 
and perilipin phosphorylation, suggesting that FGF21 signaling intersects with PKA pathway. Further study will 
address intracellular signaling pathways triggered by FGF21 in adipocytes.
Figure 6. FGF21 improves steatohepatitis of CREBH deficient mice induced by KD. (A) Creb3l3−/− mice 
were infected by Ad.GFP or Ad.hFGF21. Plasma FGF21 levels were measured 2 days after the virus infection 
(n = 4 per group). (B) Plasma glycerol and (C) NEFA levels in the adenovirus infected mice measured at days 0, 
2 and 4 on KD (n = 4 per group). (D) Adipose tissues were isolated from adenovirus-infected Creb3l3−/− mice 
fed KD for 2 days, and analyzed for HSL and perilipin phosphorylation by western blotting. (E) Hepatic TG 
levels. (F) Oil red O staining of liver sections. (G) Plasma TG and (H) ALT levels (n = 4 per group). (I) Hepatic 
mRNA levels determined by qRT-PCR (n = 4 per group). Data are shown as mean ± s.e.m. *P < 0.05 and 
**P < 0.01.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:27938 | DOI: 10.1038/srep27938
Several transcription factors have been implicated in hepatic FGF21 expression56, among which PPARα and 
CREBH appear to play the major role. Loss of PPARα or CREBH almost completely abolished fasting-induced 
hepatic FGF21 expression in mice17,18,38,47. Similarly, the loss of either PPARα or CREBH markedly reduced the 
induction of hepatic FGF21 by KD, although to lesser degrees than by fasting. Concomitant deletion of PPARα 
and CREBH further reduced hepatic FGF21 expression in KD-fed mice, indicating that PPARα and CREBH 
cooperatively regulate FGF21 expression. Consistent with this, a recent study has shown that PPARα and CREBH 
form a complex that directly binds to FGF21 promoter18. The interplay between CREBH and PPARα in the regu-
lation of FGF21 remains to be further elucidated.
The liver is the major source of circulating FGF21 in mice25. Early studies in mice revealed that FGF21 is 
induced by nutrient deprivation38,47,57, however, the effect of prolonged fasting on serum FGF21 protein level in 
humans is relatively small58,59. On the other hand, several studies including ours have demonstrated that hepatic 
FGF21 mRNA and serum FGF21 protein levels are increased in mice and humans with obesity and NAFLD38–40, 
suggesting that TG accumulation may trigger FGF21 expression in the liver. TG accumulation activates CREBH 
in the liver23, which may in turn stimulate FGF21 transcription. In line with this, a recent paper demonstrated 
that adipose tissue specific CGI-58 knockout mice are protected from fasting-induced hepatic steatosis due to 
decreased NEFA delivery to the liver, which led to impaired CREBH activation and FGF21 expression60. Given 
that prolonged fasting also induces hepatic steatosis, it is tempting to speculate that the TG accumulation under-
lies FGF21 expression in fasted mice.
While high concentration of fatty acid ligands in steatotic livers is expected to activate PPARα , it remains 
unclear how TG accumulation activates CREBH. CREBH mRNA and the nuclear CREBH(N) protein levels are 
induced in steatotic livers23. PPARα appears to play a role in the transcriptional activation CREBH in fatty livers21. 
Since CREBH has to undergo proteolytic cleavage by Golgi proteases for its activation, ER to Golgi transport of 
CREBH is expected to be a critical regulatory checkpoint. We speculate that the Golgi transport of CREBH might 
be coupled with TG accumulation or VLDL-apolipoprotein B production in the cell. Given that ER transmem-
brane transcription factors are associated with specific interacting proteins that regulate the Golgi transport61,62, 
it is tempting to speculate that CREBH might also be associated with a yet-to-be identified interaction partner 
that senses cellular TG level.
The two-hit hypothesis is widely accepted as a mechanism for the progression of simple steatosis to NASH, 
which involves oxidative stress and pro-inflammatory response in the liver as second hits63. KD caused severe 
hepatocyte death, fibrosis and inflammation in CREBH deficient mice. Interestingly, overexpression of FGF21 
ameliorated hepatic steatosis and NASH symptoms of KD-fed Creb3l3−/− mice, suggesting that FGF21 is one of 
the major CREBH targets that help alleviate steatosis and NASH. Another notable CREBH target that might be 
involved in lipotoxicity is Fsp27β , which promotes the storage of TG in lipid droplets in hepatocytes, and there-
fore is expected to reduce lipotoxicity64. We speculate that the impaired expression of Fsp27β in CREBH deficient 
mice might dsiturb TG storage in lipid droplets, exacerbating lipotoxicity and liver danage. Further studies should 
reveal the contributions of additional CREBH target genes to NAFLD and NASH.
Materials and Methods
Animal experiments. Creb3l3−/− mice were backcrossed onto a C57BL/6 background at least 10 times17. 
PPARα knockout mice (B6;129S4-Pparatm1Gonz/J) were obtained from Jackson laboratory65. Mice were housed 
in a specific pathogen free facility at the Weill Cornell Medical College on a 12h light/dark cycles and fed ad 
libitum standard chow diet (PicoLab Rodent diet 20, #5058, Lab diet) or ketogenic diet (# F3666, bio-serv). All 
animal experiments were approved by the Institutional Animal Care and Use Committee at Weill Cornell Medical 
College (Protocol #2012–0048), and performed in accordance with the approved guidelines.
Figure 7. Summary for the role of CREBH in regulating hepatic TG metabolism. CREBH is activated in 
fatty livers and promotes FGF21 production. FGF21 suppresses lipolysis, alleviating mobilization of TG from 
adipose tissue to the liver. CREBH also induces apoA-IV, apoA-V and apoC-II that stimulate LPL-mediated TG 
clearance. Loss of CREBH causes hepatic steatosis and hypertriglyceridemia.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:27938 | DOI: 10.1038/srep27938
Biochemical assays. Plasma TG, glycerol, cholesterol, NEFA, ketone bodies, ALT, insulin, and FGF21 
concentrations were determined using assay kits (Serum Triglyceride Determination Kit, Sigma; Amplex Red 
Cholesterol Assay Kit, Life technologies; NEFA-HR (2), Wako Chemicals; Autokit Total Ketone Bodies, Wako 
Chemicals; ALT Kit, Bio-Quant; Ultra Sensitive Mouse Insulin ELISA Kit, Crystal Chem; Mouse/Rat FGF-21 
Quantikine ELISA Kit, R&D Systems; Human FGF-21 Quantikine ELISA Kit, R&D Systems). Blood glucose 
levels were measured using Ascensia Breeze 2 Blood Glucose Monitoring System (Bayer). Lipids were extracted 
from liver tissues with chloroform/methanol mixture (2:1 v/v), as described previously66.
Adenoviruses. Recombinant adenoviruses that expressed human CREBH(N) were generated using 
pAdTRACK-cmv shuttle vector, as described previously66. Human FGF21 adenovirus was purchased from 
Vector Biolabs. Recombinant adenoviruses were amplified in HEK293 cells and purified using a commercial kit 
(Virapur). Mice were injected intravenously via tail vein at a doe of 3 × 109 particles of the adenoviruses per g 
body weight in 0.15 ml of saline.
Primary hepatocytes isolation and in vitro ketogenesis assay. Primary hepatocytes were prepared 
from male mice at 8–10 weeks of age. Mice were anesthetized with ketamine and xylazine. Livers were per-
fused with prewarmed liver perfusion medium (17701-038, Life Technologies) for 5 min followed by liver digest 
medium (17703-034, Life Technologies) for 10 min at 5 ml/min. Isolated hepatocytes (5 × 105 cells/well) were 
transferred to Primaria 6-well plates (353846, Corning), and cultured in medium 199 (M4530, Sigma) supple-
mented with 10% fetal bovine serum under an atmosphere of CO2 at 37 °C. For in vitro ketogenesis, sodium 
octanoate (2 mM, Sigma, C-5038) was added to culture media. The concentration of total ketone bodies in the 
culture media was determined 2, 24 and 48 h after the addition of sodium octanoate.
Glucose tolerance test. Eight- to ten-week-old WT and Creb3l3−/− mice were fasted for 16 h and then 
injected intraperitoneally with glucose (2 g/kg body weight). Blood glucose concentrations were measured before 
and 15, 30, 60, 90 and 120 min after glucose administration.
VLDL secretion assay. VLDL secretion rate in vivo was measured as previously described67. Briefly, mice 
were injected with triton WR1339 (500 mg kg–1 in saline) via tail vein following a 16 h fasting. Blood samples were 
drawn at 0, 1, 2, 3, and 4 h after the injection for TG assays.
Fatty Acid Oxidation Assay. Fatty acid oxidation activity in liver lysates was measured as previously 
described68. Briefly, 50 mg liver tissues were homogenized in 500 μ l of 250 mM sucrose. After the lysate was cleared 
by centrifugation, Triton X-100 was added to the supernatant to a final concentration of 1%. The extract was incu-
bated with a reaction buffer containing 50 mM Tris (pH 8.0), 1 mM DDT, 60 μ g/ml BSA, 25 μ M palmitoyl-CoA, 
200 μ M NAD, 1 μ M FAD, and 100 μ M CoA. NADH concentration in the reaction mixture was spectrophotomet-
rically measured at 340 nm every 30 seconds for 5 min. The rate of NADH generation was calculated, and shown 
as fatty acid oxidation activity.
Lipolysis assay. Gonadal fat pads isolated from male mice were cut into small pieces of approximately 50 mg 
each, and incubated with conditioned media from primary mouse hepatocytes infected with recombinant adeno-
viruses diluted 1:10 in phenol red-free DMEM. The culture medium was collected 3 hrs later to measure glycerol 
content using Free Glycerol Reagent (Sigma).
Histological analysis. Liver pieces were fixed in 10% formalin solution for two hours at room temperature, 
placed in 20% sucrose overnight at 4 °C, embedded in paraffin, sectioned, and stained with hematoxylin and 
eosin (H&E). Immunofluorescence staining was performed using CD45 antibody (R&D systems, AF114). Tissue 
sections were stained with Masson’s trichrome to evaluate fibrosis. For detection of neutral lipid, tissues were 
embedded in Shandon Cryomatrix (Thermo) and subjected to cryosectioning. Frozen sections were stained with 
1.8 g/l Oil Red O solution.
RNA isolation, and real time PCR. Total RNAs were isolated using TRIZOL Reagents (Life Technologies) 
according to the manufacturer’s recommendation. Complementary DNAs were generated using the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems), and subjected to SYBR-based real-time PCR 
using the Mx3005P™ system (Agilent Technologies).
Western blotting. Liver nuclear extracts were prepared as described previously23. Western blotting was 
performed using specific antibodies against ATGL (Cell Signaling, #2138), mouse CREBH66, HMGCS (Santa 
Cruz, sc-33828), HSP90 (Santa Cruz, sc-7947), Lamin B1 (Santa Cruz, sc-56145), HSL (Cell Signaling, #4170), 
phospho-HSL (Ser563) (Cell Signaling, #4139), phospho-HSL (Ser660) (Cell Signaling, #4126), perilipin (Cell 
Signaling, #9346), and PPARα (Santa Cruz, sc-9000). Following incubation with secondary antibodies, protein bands 
were visualized by SuperSignal West Pico chemiluminescence substrate (Thermofisher), imaged using Flurochem E 
system (Proteinsimple, CA, USA), and quantitated using Alphaview software (Proteinsimple, CA, USA).
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